Roche wins EC approval for Susvimo refillable eye implant in nAMD
Roche has secured European Commission approval for Susvimo (ranibizumab 100 mg/mL), a continuous-delivery treatment for neovascular age-related macular degeneration (nAMD), positioning it as an alternative to the monthly or bi-monthly intravitreal injections that define current standard of care. The Basel-based company said the approval covers the Susvimo formulation as used with its Contivue refillable ocular implant, which received a CE mark in September 2025.
nAMD affects approximately 1.7 million people across the European Union and is a leading cause of vision loss in adults over 60. Globally, around 20 million people live with the condition, a figure expected to grow as populations age. The disease develops when abnormal blood vessels proliferate beneath the macula, causing swelling and haemorrhage that can rapidly destroy central vision if untreated.
The clinical case
The approval is grounded in data from three studies: the pivotal Phase III Archway trial and two supportive studies, the Phase II Ladder study and the long-term open-label extension Portal. Archway showed that Susvimo delivered vision outcomes equivalent to monthly intravitreal ranibizumab injections. Longer-term Portal data indicated that vision was maintained for up to seven years, and that approximately 95% of patients treated with two refills per year required no additional anti-VEGF therapy.
Levi Garraway, Roche's Chief Medical Officer and Head of Global Product Development, said the approval addresses a recognised gap in adherence. "Many nAMD patients are unable to extend their dosing interval beyond every eight weeks, and 40% discontinue treatment within two years," he said. "By offering patients continuous delivery through a refillable implant, Susvimo offers a unique alternative to frequent eye injections that can help maintain vision while significantly reducing the treatment burden."
Frank Holz, Professor and Chairman of Ophthalmology at the University of Bonn, added that the fear of vision loss is compounded in clinical practice by the burden of repeated clinic visits, a problem that continuous delivery is designed to address.
Market context and competitive landscape
The nAMD treatment market is dominated by anti-VEGF agents, principally ranibizumab, aflibercept (Regeneron and Bayer's Eylea) and faricimab (Roche's own Vabysmo). Durability has become the central competitive axis, with newer agents promising extended dosing intervals to ease the administrative and psychological burden on patients and clinicians alike. Susvimo takes a different approach: rather than reformulating the molecule for longer half-life, it removes the injection cycle almost entirely, replacing it with a surgically implanted reservoir that is refilled twice a year in an outpatient setting.
That surgical step is both Susvimo's differentiator and a potential adoption barrier. Retinal specialists will need to weigh the one-time implant procedure and its associated risks against the long-term reduction in clinic burden. The FDA approved Susvimo in the United States for nAMD, diabetic macular oedema, and diabetic retinopathy; Roche will be hoping the broader EU label can follow in time, and the company has confirmed it is evaluating additional molecules for use with the Contivue platform to extend its applicability. Susvimo is also approved in Switzerland and Thailand.
With the EU representing a substantial portion of the global nAMD population, this approval is a meaningful commercial milestone. The next signposts for investors will be uptake data from early-adopting EU markets and any signal from Roche on which pipeline molecules it intends to advance through the Port Delivery Platform.